STOCK TITAN

Prelude Therapeutics Incorporated (PRLD) Revenue by Year

PRLD NASDAQ

Prelude Therapeutics Incorporated generated $12.1M in revenue in fiscal year 2025. This represents an increase of 73.4% from the prior fiscal year. Over the trailing 12 months, Q4 FY2025 through Q3 FY2026, the same line adds up to $21.6M in revenue. The table below carries 7 fiscal years, from 2019 to 2025, and the quarters Prelude Therapeutics Incorporated has filed alongside them.

FY2025 annual
Revenue $12.1M
YoY +73.4%
Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

PRLD Revenue by Fiscal Year

Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-K
Revenue$21.6M$12.1M+73.4%$7.0MN/AN/AN/AN/AN/A

TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.

PRLD Revenue by Quarter

Figures are in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-K
Revenue$5.6M-13.1%$5.7Mn/m$4.6Mn/m$5.6M$6.5M+116.7%$0$0N/A$3.0MN/AN/AN/A

What revenue means

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it.

More Prelude Therapeutics Incorporated financials

Frequently Asked Questions

Prelude Therapeutics Incorporated generated $12.1M in revenue in fiscal year 2025.

Prelude Therapeutics Incorporated (PRLD) revenue rose by 73.4% year over year, from $7.0M to $12.1M in fiscal year 2025.

Prelude Therapeutics Incorporated (PRLD) reported $21.6M in revenue over the trailing 12 months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.

Prelude Therapeutics Incorporated (PRLD) reported $5.6M in revenue in Q3 2026. This represents a decrease of 13.1% from the same quarter a year earlier.

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it. This page lists what Prelude Therapeutics Incorporated (PRLD) reported on that line in every period on record.